NEW YORK – Sherlock Biosciences on Friday said that it has licensed exclusive US rights to CRISPR-Cas12 diagnostic technology from Shanghai-based Tolo Biotech.
In return, Sherlock has granted Tolo exclusive rights to the CRISPR-Cas13 SHERLOCK diagnostic platform in Greater China. Financial details of the agreement have not been disclosed.